{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:58:20Z","timestamp":1785355100911,"version":"3.55.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gansu Province Innovation Base and Talent Plan","award":["21JR7RA015"],"award-info":[{"award-number":["21JR7RA015"]}]},{"name":"Key research and development plan of Gansu Province","award":["22YF7FA106"],"award-info":[{"award-number":["22YF7FA106"]}]},{"name":"Project of Hematology Medical Research Center of 940th Hospital of Joint Logistic Support Force","award":["2021yxky078"],"award-info":[{"award-number":["2021yxky078"]}]},{"name":"Science and Technology Program Project of Gansu Province","award":["25JRRA1184"],"award-info":[{"award-number":["25JRRA1184"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,7]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>\n                      Multiple myeloma (MM), ranking as the second most prevalent hematologic malignancy. Despite prolonged survival in MM due to novel therapies, infections remain a leading cause of mortality. While bacterial pneumonias and viral reactivations are well-documented,\n                      <jats:italic toggle=\"yes\">Listeria monocytogenes (L monocytogenes<\/jats:italic>\n                      ) (a rare but aggressive pathogen) is underrecognized in MM.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>In this report, we report a 60-year-old male patient with newly diagnosed IgA-\u03bb MM (Durie\u2013Salmon stage IIIA, ISS stage III with 1q21 amplification) who developed high-grade fever (39.8 \u00b0C) and expressive aphasia during the second cycle of bortezomib\u2013lenalidomide\u2013dexamethasone induction therapy. Initial workup revealed neutrophilia (absolute neutrophil count 1.94\u2005\u00d7\u200510\u2079\/L) with elevated inflammatory markers (C-reactive protein 118.14\u2009mg\/L). Cerebrospinal fluid analysis showed albuminocytologic dissociation (protein 1116.3\u2009mg\/L, glucose 1.77 mmol\/L, chloride 114.75 mmol\/L) without positive cultures. Contrast-enhanced brain MRI demonstrated neither abscess formation nor acute ischemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>\n                      Repeated blood cultures drawn at fever onset,\n                      <jats:italic toggle=\"yes\">L monocytogenes<\/jats:italic>\n                      bacteremia was confirmed 48 hours after-afebrile through blood culture. The patient has been diagnosed MM with bacteremia and meningitis caused by\n                      <jats:italic toggle=\"yes\">L monocytogenes<\/jats:italic>\n                      infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Empiric meropenem was initiated promptly, achieving defervescence within 72 hours. Upon availability of antimicrobial susceptibility testing (intravenous penicillin G 8 million units every 8 hours), with documented blood culture clearance at 72 hours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>On the second day of medication, the patient\u2019s aphasia symptoms were resolved, the fever subsided on the 3rd day, and the blood culture turned negative on the 10th day. The patient completed a 21-day targeted antibiotic course without neurologic sequelae and was discharged with planned resumption of anti-myeloma therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>\n                      This case underscores the need for early empiric coverage for\n                      <jats:italic toggle=\"yes\">Listeria<\/jats:italic>\n                      in MM patients with unexplained fever or neurological symptoms, particularly given its high mortality in immunocompromised hosts.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000045685","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T18:00:57Z","timestamp":1762538457000},"page":"e45685","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Listeria monocytogenes infection in multiple myeloma: A case report about a rare but lethal complication requiring heightened clinical vigilance"],"prefix":"10.1097","volume":"104","author":[{"given":"Qiuyue","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Hematology, The 940th Hospital of Joint Logistics Support Force of Chinese People\u2019s Liberation Army, Lanzhou, Gansu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The 940th Hospital of Joint Logistics Support Force of Chinese People\u2019s Liberation Army, Lanzhou, Gansu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4321-4255","authenticated-orcid":false,"given":"Tao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The 940th Hospital of Joint Logistics Support Force of Chinese People\u2019s Liberation Army, Lanzhou, Gansu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The 940th Hospital of Joint Logistics Support Force of Chinese People\u2019s Liberation Army, Lanzhou, Gansu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260729","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.1007\/s00253-016-7552-2","article-title":"Characteristics and distribution of Listeria spp., including Listeria species newly described since 2009.","volume":"100","author":"Orsi","year":"2016","journal-title":"Appl Microbiol Biotechnol"},{"key":"R2-20260729","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00277-017-3188-2","article-title":"High prevalence of hepatitis B virus infection in patients with aggressive B cell non-Hodgkin\u2019s lymphoma in China.","volume":"97","author":"Wang","year":"2018","journal-title":"Ann Hematol"},{"key":"R3-20260729","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jinf.2019.10.004","article-title":"Cutaneous listeriosis, a case series of 16 consecutive patients over 25 years.","volume":"80","author":"Pilmis","year":"2020","journal-title":"J Infect"},{"key":"R4-20260729","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/jnen\/nly077","article-title":"Histopathology of listeria meningitis.","volume":"77","author":"Engelen-Lee","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"key":"R5-20260729","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S1473-3099(16)30521-7","article-title":"Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study.","volume":"17","author":"Charlier","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R6-20260729","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1128\/microbiolspec.ARBA-0031-2017","article-title":"Antimicrobial resistance in listeria species.","volume":"6","author":"Luque-Sastre","year":"2018","journal-title":"Microbiol Spectr"},{"issue":"Suppl 3","key":"R7-20260729","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.cmi.2016.01.007","article-title":"ESCMID guideline: diagnosis and treatment of acute bacterial meningitis.","volume":"22","author":"Van De Beek","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"R8-20260729","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the international myeloma working group.","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"key":"R9-20260729","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-018-0068-5","article-title":"A systematic classification of death causes in multiple myeloma.","volume":"8","author":"Mai","year":"2018","journal-title":"Blood Cancer J"},{"key":"R10-20260729","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jamaoncol.2019.5098","article-title":"Listeria susceptibility in patients with multiple myeloma receiving daratumumab-based therapy.","volume":"6","author":"Khan","year":"2020","journal-title":"JAMA oncology"},{"key":"R11-20260729","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.2169\/internalmedicine.7509-21","article-title":"Listeria monocytogenes bacteremia during isatuximab therapy in a patient with multiple myeloma.","volume":"60","author":"Ueno","year":"2021","journal-title":"Intern Med. (Tokyo, Japan)"},{"key":"R12-20260729","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/10428194.2022.2138380","article-title":"Incidence and risk factors for bacterial infection using bortezomib, lenalidomide, and dexamethasone (RVd) in newly diagnosed multiple myeloma.","volume":"64","author":"Bici","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"R13-20260729","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1473-3099(17)30054-3","article-title":"MONALISA: a grim picture of listeriosis.","volume":"17","author":"Brouwer","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R14-20260729","first-page":"7318","article-title":"Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: a case report.","volume":"14","author":"Wu","year":"2017","journal-title":"Oncol Lett"},{"key":"R15-20260729","doi-asserted-by":"crossref","first-page":"46593","DOI":"10.18632\/oncotarget.16235","article-title":"Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis.","volume":"8","author":"Ying","year":"2017","journal-title":"Oncotarget"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045685","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:01:02Z","timestamp":1785351662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":15,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045685","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"2025-05-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}